Gilead begins UK trials of COVID-19 drug remdesivirGilead has begun testing its COVID-19 coronavirus antiviral remdesivir in the UK, announcing plans to trial the drug Share XGilead begins UK trials of COVID-19 drug remdesivirhttps://pharmaphorum.com/news/gilead-begins-uk-trials-of-covid-19-drug-remdesivir/
Pharma giants including Novartis collaborate on COVID-19 therapiesA consortium of life sciences companies including pharma giants such as Novartis and Johnson & Johnson, are to Share XPharma giants including Novartis collaborate on COVID-19 therapieshttps://pharmaphorum.com/news/collaborate-covid19-therapies/
Gilead rescinds orphan status request for COVID-19 drugGilead has rescinded its request for orphan status for its potential COVID-19 antiviral remdesivir amid a furore over Share XGilead rescinds orphan status request for COVID-19 drughttps://pharmaphorum.com/news/gilead-rescinds-orphan-status-request-for-covid-19-drug/
Gilead halts ‘compassionate use’ of potential coronavirus drugGilead has said it has stopped accepting “compassionate use” requests for its potential coronavirus antiviral remdesivir because it Share XGilead halts ‘compassionate use’ of potential coronavirus drughttps://pharmaphorum.com/news/gilead-halts-compassionate-use-of-potential-coronavirus-drug/
UK Leaders: Gilead’s Hilary Hutton-Squire on building trust with the NHSAs general manager of Gilead UK and Ireland, Hilary Hutton-Squire has been at the forefront of bringing several Share XUK Leaders: Gilead’s Hilary Hutton-Squire on building trust with the NHShttps://pharmaphorum.com/views-analysis-sales-marketing/uk-leaders-gilead-hilary-hutton-squire-on-building-trust-with-the-nhs/
Pharma staff told to work at home as Biogen deals with coronavirus outbreakThe coronavirus has begun to affect day-to-day operations at pharma companies, with Biogen dealing with an outbreak linked Share XPharma staff told to work at home as Biogen deals with coronavirus outbreakhttps://pharmaphorum.com/news/biogen-deals-with-staff-coronavirus-outbreak/
Gilead to buy immuno-oncology firm Forty Seven for $4.9bnGilead is to buy immuno-oncology firm Forty Seven for $4.9 billion, adding an antibody targeting several blood cancers Share XGilead to buy immuno-oncology firm Forty Seven for $4.9bnhttps://pharmaphorum.com/news/gilead-to-buy-immuno-oncology-firm-forty-seven-for-4-9bn/
Chinese biotech censured for misleading coronavirus drug claimsChina’s BrightGene Bio-Medical Technology has been censured by the Shanghai Stock Exchange for wrongly claiming it is able Share XChinese biotech censured for misleading coronavirus drug claimshttps://pharmaphorum.com/news/chinese-biotech-censured-for-misleading-coronavirus-drug-claims/
Gilead launches phase 3 trials of coronavirus antiviral remdesivirGilead has said it has begun two phase 3 trials of its potential COVID-19 coronavirus antiviral remdesivir in Share XGilead launches phase 3 trials of coronavirus antiviral remdesivirhttps://pharmaphorum.com/news/gilead-launches-phase-3-trials-of-coronavirus-antiviral-remdesivir/
